Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment (Q43022171)

12 November 2017

title

Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment (English)

1 reference

triple-negative breast cancer

12 November 2017

main subject

1 reference

1 reference

5

Robert Elashoff

1 reference

12 November 2017

Helena R Chang

1

1 reference

12 November 2017

John Glaspy

2

1 reference

12 November 2017

Mary Ann Allison

3

1 reference

12 November 2017

Frederic C Kass

4

1 reference

12 November 2017

Debra U Chung

6

1 reference

12 November 2017

Jeffrey Gornbein

7

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

12 November 2017

1 reference

12 November 2017

volume

116

1 reference

12 November 2017

issue

18

1 reference

12 November 2017

page(s)

4227-4237

1 reference

Dose-response effect of adjuvant chemotherapy in breast cancer

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Primary systemic therapy in operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Primary chemotherapy in breast cancer: correlation between tumor response and patient outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Repeated observation of breast tumor subtypes in independent gene expression data sets

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25309

7 January 2021

Identifiers

DOI

10.1002/CNCR.25309

1 reference

12 November 2017

1 reference